InSite Vision to advance topical anti-inflammatory product

January 6, 2010

InSite Vision Inc. has announced plans to study ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery, in clinical trials pending the completion of investigational new drug-enabling toxicology studies in the first half of this year.

Alameda, CA

-InSite Vision Inc. has announced plans to study ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery, in clinical trials pending the completion of investigational new drug-enabling toxicology studies in the first half of this year.

The product combines a lower concentration of bromfenac with InSite’s proprietary bio-adhesive polymer technology (DuraSite). The combination “create[s] a promising therapeutic that we believe will offer significant safety, efficacy, and dosing advantages,” said Kamran Hosseini, MD, PhD, chief medical officer and vice president, clinical affairs. “In preclinical studies, ISV-303 appears to offer compelling benefits that we hope will translate into an improved, easy-to-use eye drop.”

ISV-303 is intended to extend the duration of drug residence on the eye’s surface to facilitate better penetration and thus reduce dosing while potentially improving both efficacy and side effect profiles. In preclinical studies to date, ISV-303 demonstrated a superior delivery and ocular distribution profile when compared with the commercially available product, according to InSite Vision. Further, ISV-303’s improved distribution profile was consistent across all ocular tissues, including both the front and back of the eye, according to the company.